| Literature DB >> 31175471 |
Subin Hwang1, Hyejeong Park2, Youngha Kim2, Danbee Kang2,3, Ho Suk Ku1, Juhee Cho2,3, Jung Eun Lee4, Wooseong Huh4, Eliseo Guallar2,5, Gee Young Suh6,7, Hye Ryoun Jang8.
Abstract
BACKGROUND: Although no specific treatment facilitates renal tubular regeneration in acute kidney injury (AKI), the rapid increase in aging populations with more comorbidities and advances in critical care management are expected to change the epidemiology of AKI. However, few recent studies dissected the current epidemiologic characteristics of critically ill patients with AKI. We investigated recent epidemiologic changes in severe AKI in critically ill patients.Entities:
Keywords: Acute kidney injury; Critically ill patients; Intensive care unit; Mortality
Year: 2019 PMID: 31175471 PMCID: PMC6555834 DOI: 10.1186/s13613-019-0534-7
Source DB: PubMed Journal: Ann Intensive Care ISSN: 2110-5820 Impact factor: 6.925
Fig. 1Yearly trends of acute kidney injury in critically ill patients in Korea between 2008 and 2015. Bars represent absolute number of critically ill patients with acute kidney injury (AKI); lines represent proportion of critically ill patients with AKI among all ICU patients. Incidence increased from 7.4% in 2008 to 8.3% in 2015 (p for trend < 0.001)
Characteristics of critically ill patients by the presence of acute kidney injury in Korea, 2008 to 2015
| Overall | No AKI | AKI | ||
|---|---|---|---|---|
| Number of patients | 1,678,089 | 1,544,968 | 133,121 | |
| Gender | < 0.001b | |||
| Male | 962,594 (57.4) | 883,803 (57.2) | 78,791 (59.2) | |
| Female | 715,495 (42.6) | 661,165 (42.8) | 54,330 (40.8) | |
| Age, years | 64.2 (15.5) | 64 (15.5) | 67.2 (15.2) | < 0.001c |
| Charlson index | 2 (1–4) | 2 (1–4) | 3 (1–5) | < 0.001d |
| Comorbidity | ||||
| Myocardial infarction | 95,571 (5.7) | 87,606 (5.7) | 7965 (6.0) | < 0.001b |
| Congestive heart failure | 195,381 (11.6) | 174,071 (11.3) | 21,310 (16.0) | < 0.001b |
| Peripheral vascular disease | 276,411 (16.5) | 251,706 (16.3) | 24,705 (18.6) | < 0.001b |
| Cerebrovascular disease | 421,600 (25.1) | 388,951 (25.2) | 32,649 (24.5) | < 0.001b |
| Rheumatologic disease | 81,210 (4.8) | 73,570 (4.8) | 7640 (5.7) | <0.001b |
| Peptic ulcer disease | 517,857 (30.9) | 475,376 (30.8) | 42,481 (31.9) | < 0.001b |
| Liver disease | 496,684 (29.6) | 451,074 (29.2) | 45,610 (34.3) | < 0.001b |
| Diabetes mellitus | 570,759 (34.0) | 513,760 (33.3) | 56,999 (42.8) | < 0.001b |
| Renal disease | 64,066 (3.8) | 48,509 (3.1) | 15,557 (11.7) | < 0.001b |
| Cancer | 311,745 (18.6) | 287,640 (18.6) | 24,105 (18.1) | < 0.001b |
| AIDS/HIV | 854 (0.1) | 754 (0.1) | 100 (0.1) | < 0.001b |
| Type of hospital | < 0.001b | |||
| Tertiary | 659,767 (39.3) | 607,539 (39.3) | 52,228 (39.2) | |
| General | 962,395 (57.4) | 885,015 (57.3) | 77,380 (58.1) | |
| Nursing care hospital | 1089 (0.1) | 963 (0.1) | 126 (0.1) | |
| Other | 54,838 (3.3) | 51,451 (3.3) | 3387 (2.5) | |
| Management procedures | ||||
| Mechanical ventilation | 371,592 (22.1) | 303,676 (19.7) | 67,916 (51.0) | < 0.001b |
| ECMO | 4618 (0.3) | 2059 (0.1) | 2559 (1.9) | < 0.001b |
| Vasopressor drugs | 190,296 (11.3) | 148,062 (9.6) | 42,234 (31.7) | < 0.001b |
| Organ dysfunction | ||||
| Respiratory | 68,061 (4.1) | 49,839 (3.2) | 18,222 (13.7) | < 0.001b |
| Cardiovascular | 144,774 (8.6) | 10,5992 (6.9) | 38,782 (29.1) | < 0.001b |
| Hepatic | 7475 (0.5) | 5216 (0.3) | 2259 (1.7) | < 0.001b |
| Hematologic | 93,124 (5.6) | 67,683 (4.4) | 25,441 (19.1) | < 0.001b |
| Neurologic | 38,466 (2.3) | 31,913 (2.1) | 6553 (4.9) | < 0.001b |
| Outcomes | ||||
| Hospital mortality | 203,373 (12.1) | 151,550 (9.8) | 51,823 (38.9) | < 0.001b |
| ICU length of stay, days | 3 (2–8) | 3 (2–7) | 8 (3–22) | < 0.001d |
| Hospital length of stay, days | 13 (7–24) | 13 (7–24) | 17 (8–35) | < 0.001d |
| Total cost, USDa | 5208 (2617–8814) | 5111 (2566–8487) | 7386 (3347–15,751) | < 0.001d |
Values are numbers and proportions, except for age and Charlson index (mean and SD), ICU length of stay, hospital length of stay, and total cost (median and interquartile)
AIDS acquired immune deficiency syndrome, AKI acute kidney injury, HIV human immunodeficiency virus, ECMO extracorporeal membrane oxygenation, ICU intensive care unit, USD US dollars
a1 USD = 1158 Korean won (exchange rate as of December 1, 2015)
bChi-squared test
cStudent’s t test
dWilcoxon–Mann–Whitney test
Fig. 2In-hospital mortality rate in critically ill patients with acute kidney injury in Korea between 2008 and 2015. Bars represent absolute number of deaths in critically ill patients with acute kidney injury (AKI); lines represent mortality of critically ill patients with AKI. Mortality decreased from 39.1 to 37.2% (p for trend < 0.001)
Odds ratio (95% CI) for acute kidney injury in intensive care unit hospitalization in Korea, 2008 to 2015
| Crude odds ratio (95% CI) | Adjusted odds ratio (95% CI) | |||
|---|---|---|---|---|
| Age (continuous) | 1.02 (1.02–1.02) | < .001 | 1.01 (1.01–1.01) | < .001 |
| Gender, male | 1.09 (1.08–1.10) | < .001 | 1.02 (1.02–1.03) | < .001 |
| Tertiary hospital | 0.94 (0.91–0.97) | < .001 | 1.05 (1.05–1.06) | 0.365 |
| Year | 1.02 (1.02–1.02) | < .001 | 1.18 (1.17–1.20) | < .001 |
| Charlson index | 1.08 (1.08–1.09) | < .001 | 0.98 (0.95–1.02) | < .001 |
| Comorbidity | ||||
| Myocardial infarction | 1.00 (0.97–1.02) | 0.857 | 0.85 (0.83–0.87) | < .001 |
| Congestive heart failure | 1.50 (1.48–1.53) | < .001 | 1.16 (1.14–1.18) | < .001 |
| Peripheral vascular disease | 1.12 (1.15–1.18) | < .001 | 0.94 (0.93–0.96) | < .001 |
| Cerebrovascular disease | 0.97 (0.95–0.98) | < .001 | 0.78 (0.77–0.79) | < .001 |
| Rheumatologic disease | 1.23 (1.20–1.26) | < .001 | 0.98 (0.96–1.01) | 0.239 |
| Peptic ulcer disease | 1.07 (1.06–1.08) | < .001 | 0.88 (0.87–0.89) | < .001 |
| Liver disease | 1.28 (1.27–1.30) | < .001 | 0.99 (0.98–1.01) | 0.431 |
| Diabetes mellitus | 1.61 (1.60–1.63) | < .001 | 1.26 (1.25–1.28) | < .001 |
| Renal disease | 4.23 (4.15–4.32) | < .001 | 3.45 (3.37–3.52) | < .001 |
| Cancer | 1.06 (1.05–1.08) | < .001 | 0.72 (0.70–0.74) | < .001 |
| AIDS/HIV | 1.46 (1.18–1.81) | < .001 | 0.85 (0.67–1.06) | 0.151 |
| Organ dysfunction | ||||
| Respiratory | 4.84 (4.75–4.94) | < .001 | 2.97 (2.91–3.04) | < .001 |
| Cardiovascular | 5.89 (5.81–5.97) | < .001 | 4.24 (4.18–4.31) | < .001 |
| Hepatic | 4.56 (4.33–4.81) | < .001 | 3.46 (3.26–3.67) | < .001 |
| Hematologic | 5.24 (5.15–5.33) | < .001 | 3.64 (3.57–3.70) | < .001 |
| Neurologic | 2.49 (2.42–2.56) | < .001 | 1.84 (1.78–1.90) | < .001 |
Adjusted for age, gender, tertiary hospital, year, Charlson index, myocardial infarction, congestive heart failure, cerebrovascular disease, rheumatologic disease, peptic ulcer disease, liver disease, diabetes, renal disease, cancer, AIDS/HIV, and organ dysfunction (respiratory, cardiovascular, hepatic, hematologic, neurologic)
AIDS acquired immune deficiency syndrome, CI confidence interval, HIV human immunodeficiency virus
aMixed effects logistic regression model
Adjusted odds ratios (95% CI) of management procedures and outcomes associated with critically ill patients with acute kidney injury
| No. of patients | No. of AKI patients | Crude odds ratio (95% CI) | Adjusted odds ratio (95% CI) | |||
|---|---|---|---|---|---|---|
| In-hospital mortality | 203,373 | 51,823 | 6.33 (6.25–6.42) | < 0.001 | 3.74 (3.68–3.79) | < 0.001 |
| Mechanical ventilation | 371,592 | 67,916 | 4.72 (4.66–4.77) | < 0.001 | 2.87 (2.83–2.91) | < 0.001 |
| ECMO | 4618 | 2559 | 16.18 (15.24–17.17) | < 0.001 | 6.99 (6.53–7.19) | < 0.001 |
| Vasopressor drugs | 181,936 | 40,523 | 4.71 (4.64–4.77) | < 0.001 | 2.75 (2.71–2.79) | < 0.001 |
Adjusted for age, gender, tertiary hospital, year, Charlson index, myocardial infarction, congestive heart failure, cerebrovascular disease, rheumatologic disease, peptic ulcer disease, liver disease, diabetes, renal disease, cancer, AIDS/HIV, and organ dysfunction (respiratory, cardiovascular, hepatic, hematologic, neurologic)
AIDS acquired immune deficiency syndrome, AKI acute kidney injury, CI confidence interval, ECMO extracorporeal membrane oxygenation, HIV human immunodeficiency virus
aMixed effects logistic regression model